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Intestinal parasitic infections rank amongst the most
important causes of morbidity and mortality, especially
so in the developing countries and tropics. In a high
proportion of cases, protozoal and helminthic infections
tend to coexist and have to be treated with antiprotozoal
and anthelminthic drug given together. This makes such
therapy less affordable to the majority of the sufferers,
who are from the economically weaker sections of the
society. Against this backdrop, availability of nitazoxanide
offers a new ray of hope. It  is the only agent that has
broad coverage against both common intestinal parasitic
protozoa and helminths. Nitazoxanide was originally
discovered in  1980’s by Jean Francois Rossignol
at the Pasteur Institute. Initial studies demonstrated
activity aganist tapeworms. In vitro studies demonstrated
much broader activity. Rossignol subsequently led the
preclinical and clinical development of albendazole and
halofantrine. In 1994 it gained importance after its broad
spectrum activity was recognized against common
emerging and resistant intestinal protozoa and intestinal
helminths (1-6).
Nitazoxanide, a 2 acetyloxy-N (5-nitro-2-thiazolyl)
benzamide is well absorbed from the gut. It interferes
with pyruvate ferredoxin oxidoreductase(PFOR) enzyme
dependent electron transfer reaction which is important
for anaerobic glucose energy metabolism. This results in
cell swelling, membrane damage and vacuole injury of
the trophozoites, resulting in dysfunction of the parasite.
The drug is metabolized to the main active metabolite
desacetyl nitazoxanide(tizoxanide). Excretion of the drug
occurs in urine, bile and faeces(3,5). Nitazoxanide is active
against protozoa such as giardia intestinalis, entameba
histolytica and cryptosporidium parvum, helminths such
as ascaris lumbricoides, ancylostoma duodenale,
enterobius vermicularis, hymenolepis nana, trichuris
trichura, strongyloides stercoralis, taenis saginata and
fasciola hepatica. It is also effective against bacteroides,
helicobacter pylori and clostridium species (5-7).
In vitro studies reveal that nitazoaxanide and its
metabolite tizoxanide are 8 times and 1.5 times more
active than metronidazole and other 5-nitroimidazole
compounds against giardiasis and amoebiasis respectively.
It resolves diarrhoea and associated symptoms within 7 days
of initation of therapy. It also eliminates cysts or trophozoites
from the stools in the post treatment  period (8-10). Not
only this diahorea and entritis associated with blastocystitis
hominus also has been shown to resolve with nitazoxamide
therapy (11).
Cryptosporidiosis occurs not only in AIDS patients but
must also be looked for in immunologically competent
children with diarrhoea. It is relatively difficult to treat
this infection. A 3 day course of nitazoxanide has
demonstrated unsurpassed efficacy and commendable
safety in controlling diarrhoea in patients with normal
immunity. It resolves diarrhoea and associated symptoms
within 7 days of initation of therapy. When given for several
weeks, nitazoxanide appears promising for the treatment
of cryptosporidial diarrhoea in immunocompromised
patients. It has been shown to reduce cryptosporidial
diarrheoa by approximately 50% in half of the HIV
positive patients studied (8,9,12).
Nitazoxamide appears very promising for the treatment
of ascariasis, enterobiasis, trichuriasis, hookwork
infection, hymenolepiasis and strongyloidiasis. The results
were closely comparable to broad spectrum anthelminthic
drugs viz, albendazole, menbendazole, thiabendazole and
praziquentel. Preclinical, in vitro studies have demonstrated
that this drug has significant activity against Clostridium
difficile, Campylobacter jejuni and Helicobacter pylori.
Its therapeutic potential in anaerobic and microaerophilic
bacterial infections is likely to undergo clinical evaluation.Vol. 8 No. 1, January-March 2006 61
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The recommended dosage in children is 15mg/kg/day
divided in 2 doses orally for 3 days in most of the protozoal
and helminthic infections. In cryptosporidiosis when
given100mg b.i.d and 200mg b.i.d in 1-4 years and 4-11
years old children respectively for 7 days, produces
resolution of diarrhea in 80% and oocyst eradication in
more than 95% cases (7). In HIV positive children with
cryptosporidiosis, the duration of therapy is longer than
32 weeks (7,9,10,13).
The adverse effects reported are abdominal pain,
diarrhoea, vomiting, headache, flatulence, fever, malaise,
rhinitis, discoloration of urine, increased transaminases and
increased creatinine levels. This drug should be prescribed
with food to decrease the gastrointestinal effects (1-3).
Nitazoxanide is the only agent that has broad coverage
against both common intestinal parasitic protozoa and
helminths. This offers the convenience of single drug
therapy of both type of infections. Considering the cost
of repeated physician visits involved in the management
of intestinal parasitic infections, the use of nitazoxanide
is more cost effective than current treatment practices.
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